Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 8/20 | 0.54 |
| ▸ | CRBN | Q96SW2 | 6/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.42 |
| ▸ | TNKS | O95271 | 1/20 | 0.41 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.35 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3227871 | 1.00 | SCD (0.54) | SCDCRBNDDB1TNKSTNKS2 | |
| SCHEMBL3216390 | 0.94 | SCD (0.46) | SCDCRBNTNKSTNKS2IDO1 | |
| SCHEMBL3216383 | 0.94 | SCD (0.46) | SCDCRBNTNKSTNKS2IDO1 | |
| SCHEMBL3226005 | 0.87 | SCD (0.57) | SCDTNKSTNKS2IDO1AVPR1A | |
| SCHEMBL3226001 | 0.87 | SCD (0.57) | SCDTNKSTNKS2IDO1AVPR1A | |
| SCHEMBL3222592 | 0.81 | SCD (0.49) | SCDTNKSTNKS2IDO1AVPR1A | |
| SCHEMBL3226186 | 0.81 | SCD (0.49) | SCDTNKSTNKS2IDO1AVPR1A | |
| SCHEMBL3259787 | 0.80 | SCD (0.55) | SCDTNKSTNKS2IDO1AVPR1A | |
| SCHEMBL3259786 | 0.80 | SCD (0.55) | SCDTNKSTNKS2IDO1AVPR1A | |
| SCHEMBL3229299 | 0.76 | SCD (0.68) | SCDTNKSTNKS2IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575167-B2 | Spiro compounds having stearoyl-CoA desaturase action | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-05 | — | — | US | disclosed |
| US-20100069351-A1 | SPIRO COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069351-A1 | SPIRO COMPOUND AND USE THEREOF | SCD, SPR, SCD5 | SCD 1/4885CRBN 3212/4885DDB1 1722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.